Editas Medicine, Inc.

Editas Medicine, Inc. reported a net loss of $160.1 million for fiscal year 2025, driven by an operating loss of $160.0 million. Total revenue from collaboration and other research and development activities was $40.5 million. Operating expenses totaled $200.5 million, consisting of $90.0 million in research and development, $49.9 million in general and administrative expenses, and $60.7 million in restructuring and impairment charges. The company ended the year with $186.5 million in total assets, including $146.6 million in cash and cash equivalents, and $27.3 million in total stockholders' equity. Net cash used in operating activities was $165.2 million, while net cash provided by investing and financing activities was $138.7 million and $40.5 million, respectively. The company's financial position reflects ongoing investment in research and development while managing liquidity through financing activities.

Key Takeaways